Prostate Cancer Clinical Trial

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Summary

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

View Full Description

Full Description

Primary Objective:

To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI.
To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to treatment and predict progression free survival (PFS) at 24 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must be at least 18 years of age;
Patients must be able to provide informed consent;
Histologically proven low-grade or intermediate-grade prostate cancer (PC)
Scheduled to undergo targeted local therapy (HDR brachytherapy).

Exclusion Criteria:

Inability to lie still for the entire imaging time;
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance;
Metallic implants (contraindicated for MRI).

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

4

Study ID:

NCT04264208

Recruitment Status:

Terminated

Sponsor:

Andrei Iagaru

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford Cancer Center
Stanford California, 94304, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

4

Study ID:

NCT04264208

Recruitment Status:

Terminated

Sponsor:


Andrei Iagaru

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.